CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Dosage Protocol
CJC-1295 NO DAC + Ipamorelin Dosage Chart
The CJC-1295 NO DAC + Ipamorelin peptide blend is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide). Typical daily range: 100–300 mcg of each peptide once daily (gradual titration). Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe. Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS)[1][2]. CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases[1], while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
Week Daily Dose (mcg each) Units (per injection) (mL) Weeks 1–2 100 mcg each 3 units (0.03 mL) Weeks 3–4 150 mcg each 4.5 units (0.045 mL) Weeks 5–6 200 mcg each 6 units (0.06 mL) Weeks 7–12 250–300 mcg each 7.5–9 units (0.075–0.09 mL)
Frequency: Inject once daily subcutaneously, typically before bed or upon waking[4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake). Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
Peptide Vials (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each):
8 weeks ≈ 3 vials 12 weeks ≈ 4 vials 16 weeks ≈ 5 vials Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes):
Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
8 weeks (3 vials): 9 mL → 1 × 10 mL bottle 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100-count boxes 12 weeks: 168 swabs → recommend 2 × 100-count boxes 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Protocol Overview
Concise summary of the once-daily regimen.
Goal: Support pulsatile GH release through synergistic GHRH + GHS stimulation[4]. Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired). Dose Range: 100–300 mcg of each peptide daily with gradual titration. Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements. Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
Start: 100 mcg each peptide daily; increase by ~50 mcg every 1–2 weeks as tolerated. Target: 200–300 mcg each peptide daily by Weeks 5–12. Frequency: Once per day (subcutaneous). Cycle Length: 8–12 weeks; optional extension to 16 weeks. Timing: Typically before bed or upon waking; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure. Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw. Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes; dispose in a sharps container. Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation. Inject slowly; wait a few seconds before withdrawing the needle. Document daily dose and site rotation to maintain consistency. For doses under 10 units, use 30- or 50-unit syringes for better precision.
How This Works
CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary[1]. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration[1]. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours[5] that elicits a rapid GH pulse peaking around 40 minutes post-dose[6]. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels[3]. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways[4].
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
Supports sustained GH and IGF-1 elevation through pulsatile release patterns[1][2]. Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation[3]. Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models[2]. Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions. Some individuals report increased appetite, water retention, or tingling sensations.
Lifestyle Factors
Complementary strategies for best outcomes.
Pair with a balanced, protein-forward diet tailored to energy needs. Combine resistance training and aerobic activity to reinforce metabolic adaptations. Prioritize sleep quality, as GH is predominantly released during deep sleep. Manage stress to support optimal hormonal balance and recovery.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7].
Clean the vial stopper and skin with alcohol; allow to dry. Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8]. Do not aspirate for subcutaneous injections; inject slowly and steadily[7]. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].
Recommended Source
We recommend Pure Lab Peptides for high-purity CJC-1295 NO DAC + Ipamorelin (10 mg Blend).
Why Pure Lab Peptides?
High-purity, third-party-tested lots with batch COAs. Consistent, ISO-aligned handling and documentation. Reliable fulfillment to maintain cold-chain integrity.
Shop at Pure Lab Peptides
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
PubMed — Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults
PubMed — Once-daily CJC-1295 normalizes growth in GHRH knockout mouse
PubMed — Ipamorelin, the first selective growth hormone secretagogue
PMC — Beyond the androgen receptor: GH secretagogues in body composition management
PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers
PubMed — Ipamorelin GH pulse kinetics and timing studies
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration)
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration)
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route
Frontiers in Endocrinology — Growth hormone secretagogues: history and clinical applications
Endocrine Reviews — Ghrelin and growth hormone secretagogues: physiology and applications
Pure Lab Peptides — CJC-1295 NO DAC + Ipamorelin (10 mg Blend) product page